WO2020253352A1 - 一种化合物及其制备方法和应用 - Google Patents
一种化合物及其制备方法和应用 Download PDFInfo
- Publication number
- WO2020253352A1 WO2020253352A1 PCT/CN2020/085842 CN2020085842W WO2020253352A1 WO 2020253352 A1 WO2020253352 A1 WO 2020253352A1 CN 2020085842 W CN2020085842 W CN 2020085842W WO 2020253352 A1 WO2020253352 A1 WO 2020253352A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- group
- formula
- unsubstituted
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 229940080328 Arginase inhibitor Drugs 0.000 claims abstract description 8
- -1 oxo-oxazolidinyl Chemical group 0.000 claims description 49
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 40
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 27
- 125000002252 acyl group Chemical group 0.000 claims description 26
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 229910052805 deuterium Inorganic materials 0.000 claims description 14
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 11
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 10
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 5
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 5
- 229910005965 SO 2 Inorganic materials 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 5
- 229920002866 paraformaldehyde Polymers 0.000 claims description 5
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 5
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 5
- 229920002554 vinyl polymer Polymers 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 229940126585 therapeutic drug Drugs 0.000 claims description 3
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 150000001975 deuterium Chemical group 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 22
- 239000012453 solvate Substances 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 102000004452 Arginase Human genes 0.000 description 49
- 108700024123 Arginases Proteins 0.000 description 49
- 238000006243 chemical reaction Methods 0.000 description 38
- 239000003112 inhibitor Substances 0.000 description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 31
- 239000000243 solution Substances 0.000 description 24
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical class O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 150000002430 hydrocarbons Chemical group 0.000 description 18
- 239000004475 Arginine Substances 0.000 description 15
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 15
- 235000009697 arginine Nutrition 0.000 description 15
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000002994 raw material Substances 0.000 description 14
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 229930064664 L-arginine Natural products 0.000 description 8
- 235000014852 L-arginine Nutrition 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- JJJDLCOQQVLSCH-UHFFFAOYSA-N C1COCC1OC2=CC=C(C=C2)C3=CC=C(C=C3)C=O Chemical compound C1COCC1OC2=CC=C(C=C2)C3=CC=C(C=C3)C=O JJJDLCOQQVLSCH-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000012089 stop solution Substances 0.000 description 5
- 0 *C1(COCC1)Oc(cc1)ccc1-c1ccc(CN[C@](C2)C[C@]2C(CCCCB(O)O)(C(O)=O)N)cc1 Chemical compound *C1(COCC1)Oc(cc1)ccc1-c1ccc(CN[C@](C2)C[C@]2C(CCCCB(O)O)(C(O)=O)N)cc1 0.000 description 4
- JTTIGLYPLMYHAT-UHFFFAOYSA-N 4-(4-methoxyphenyl)benzaldehyde Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C=O)C=C1 JTTIGLYPLMYHAT-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 102100021723 Arginase-1 Human genes 0.000 description 4
- 101710129000 Arginase-1 Proteins 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 150000001642 boronic acid derivatives Chemical class 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229940126586 small molecule drug Drugs 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- WSFMNWXMJBFYQT-UHFFFAOYSA-N 4-(4-acetylphenyl)benzaldehyde Chemical compound C1=CC(C(=O)C)=CC=C1C1=CC=C(C=O)C=C1 WSFMNWXMJBFYQT-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YLYATTKCVLJFHG-UHFFFAOYSA-N C#CC1=CC=C(C=C1)C2=CC=C(C=C2)C=O Chemical group C#CC1=CC=C(C=C1)C2=CC=C(C=C2)C=O YLYATTKCVLJFHG-UHFFFAOYSA-N 0.000 description 3
- JJJDLCOQQVLSCH-KRWDZBQOSA-N C1COC[C@H]1OC2=CC=C(C=C2)C3=CC=C(C=C3)C=O Chemical compound C1COC[C@H]1OC2=CC=C(C=C2)C3=CC=C(C=C3)C=O JJJDLCOQQVLSCH-KRWDZBQOSA-N 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 3
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 3
- VXWBQOJISHAKKM-UHFFFAOYSA-N (4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1 VXWBQOJISHAKKM-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- GFJHRBBGNBYNEH-UHFFFAOYSA-N 4-[4-(cyclopropylmethoxy)phenyl]benzaldehyde Chemical compound O=Cc1ccc(cc1)-c1ccc(OCC2CC2)cc1 GFJHRBBGNBYNEH-UHFFFAOYSA-N 0.000 description 2
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 description 2
- 101710186578 Arginase-2, mitochondrial Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- JJJDLCOQQVLSCH-QGZVFWFLSA-N C1COC[C@@H]1OC2=CC=C(C=C2)C3=CC=C(C=C3)C=O Chemical compound C1COC[C@@H]1OC2=CC=C(C=C2)C3=CC=C(C=C3)C=O JJJDLCOQQVLSCH-QGZVFWFLSA-N 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 2
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- TXWOGHSRPAYOML-UHFFFAOYSA-M cyclobutanecarboxylate Chemical compound [O-]C(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-M 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229910001437 manganese ion Inorganic materials 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- FECGNJPYVFEKOD-VMPITWQZSA-N resminostat Chemical compound C1=CC(CN(C)C)=CC=C1S(=O)(=O)N1C=C(\C=C\C(=O)NO)C=C1 FECGNJPYVFEKOD-VMPITWQZSA-N 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000011345 viscous material Substances 0.000 description 2
- WQFIAVZQVYASHZ-BYPYZUCNSA-N (2s)-5-(diaminomethylideneamino)-2-(hydroxyamino)pentanoic acid Chemical compound NC(=N)NCCC[C@H](NO)C(O)=O WQFIAVZQVYASHZ-BYPYZUCNSA-N 0.000 description 1
- ZZJLMZYUGLJBSO-LAEOZQHASA-N (3R,4S)-3-amino-1-[(2S)-2-aminopropanoyl]-4-(3-boronopropyl)pyrrolidine-3-carboxylic acid Chemical compound N[C@]1(CN(C[C@@H]1CCCB(O)O)C([C@H](C)N)=O)C(=O)O ZZJLMZYUGLJBSO-LAEOZQHASA-N 0.000 description 1
- XDPCNPCKDGQBAN-SCSAIBSYSA-N (3r)-oxolan-3-ol Chemical compound O[C@@H]1CCOC1 XDPCNPCKDGQBAN-SCSAIBSYSA-N 0.000 description 1
- XDPCNPCKDGQBAN-BYPYZUCNSA-N (3s)-oxolan-3-ol Chemical compound O[C@H]1CCOC1 XDPCNPCKDGQBAN-BYPYZUCNSA-N 0.000 description 1
- RRRYTONNYRBSRP-UHFFFAOYSA-N (4-ethynylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C#C)C=C1 RRRYTONNYRBSRP-UHFFFAOYSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 1
- ICPFATCSVAXDEA-UHFFFAOYSA-N 3-(4-bromophenoxy)oxolane Chemical compound C1=CC(Br)=CC=C1OC1COCC1 ICPFATCSVAXDEA-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- XDPCNPCKDGQBAN-UHFFFAOYSA-N 3-hydroxytetrahydrofuran Chemical compound OC1CCOC1 XDPCNPCKDGQBAN-UHFFFAOYSA-N 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 229940096921 Arginase I inhibitor Drugs 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BQCRBYVCKYIGCS-CYBMUJFWSA-N C(CCB)C[C@](N)(C(=O)O)CCN1CCCCC1 Chemical compound C(CCB)C[C@](N)(C(=O)O)CCN1CCCCC1 BQCRBYVCKYIGCS-CYBMUJFWSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- JEOPCEBFJBDPSL-HCGNOCCLSA-N C=Cc(cc1)ccc1-c1ccc(CN[C@H](C2)C[C@H]2C(CCCCB(O)O)(C(O)=O)N)cc1 Chemical compound C=Cc(cc1)ccc1-c1ccc(CN[C@H](C2)C[C@H]2C(CCCCB(O)O)(C(O)=O)N)cc1 JEOPCEBFJBDPSL-HCGNOCCLSA-N 0.000 description 1
- RDBFPVIGDKZFDJ-HCGNOCCLSA-N CC(c(cc1)ccc1-c1ccc(CN[C@H](C2)C[C@H]2C(CCCCB(O)O)(C(O)=O)N)cc1)=O Chemical compound CC(c(cc1)ccc1-c1ccc(CN[C@H](C2)C[C@H]2C(CCCCB(O)O)(C(O)=O)N)cc1)=O RDBFPVIGDKZFDJ-HCGNOCCLSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WFBHRSAKANVBKH-UHFFFAOYSA-N N-hydroxyguanidine Chemical compound NC(=N)NO WFBHRSAKANVBKH-UHFFFAOYSA-N 0.000 description 1
- IJTNSBVJKJSIKJ-SCABXCBLSA-N NC(CCCCB(O)O)(C(C1)CC1N(Cc(cc1)ccc1-c(cc1)ccc1O[C@@H]1COCC1)Cc(cc1)ccc1-c(cc1)ccc1O[C@@H]1COCC1)C(O)=O Chemical compound NC(CCCCB(O)O)(C(C1)CC1N(Cc(cc1)ccc1-c(cc1)ccc1O[C@@H]1COCC1)Cc(cc1)ccc1-c(cc1)ccc1O[C@@H]1COCC1)C(O)=O IJTNSBVJKJSIKJ-SCABXCBLSA-N 0.000 description 1
- XCOFTJZXOQDMBB-HJEDJERISA-N NC(CCCCB(O)O)(C(C1)CC1NCc(cc1)ccc1-c(cc1)ccc1O[C@@H]1COCC1)C(O)=O Chemical compound NC(CCCCB(O)O)(C(C1)CC1NCc(cc1)ccc1-c(cc1)ccc1O[C@@H]1COCC1)C(O)=O XCOFTJZXOQDMBB-HJEDJERISA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 101150098694 PDE5A gene Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- AYJVDOMUBHORKK-UHFFFAOYSA-N [4-(cyclopropylmethoxy)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OCC1CC1 AYJVDOMUBHORKK-UHFFFAOYSA-N 0.000 description 1
- FCVHBUFELUXTLR-UHFFFAOYSA-N [Li].[AlH3] Chemical class [Li].[AlH3] FCVHBUFELUXTLR-UHFFFAOYSA-N 0.000 description 1
- VYMCYRPQICLHKC-WCCKRBBISA-N acetic acid;(2s)-2-amino-5-[[amino-(hydroxyamino)methylidene]amino]pentanoic acid Chemical compound CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)NO VYMCYRPQICLHKC-WCCKRBBISA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- ORBBTCHHNMWMCP-UHFFFAOYSA-K cycloocta-1,5-diene trichloroiridium Chemical class [Ir](Cl)(Cl)Cl.C1=CCCC=CCC1 ORBBTCHHNMWMCP-UHFFFAOYSA-K 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- CXSYDLCMCLCOCA-UHFFFAOYSA-N hexylboronic acid Chemical compound CCCCCCB(O)O CXSYDLCMCLCOCA-UHFFFAOYSA-N 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- IHLHSAIBOSSHQV-UHFFFAOYSA-N methyl 3-oxocyclobutane-1-carboxylate Chemical compound COC(=O)C1CC(=O)C1 IHLHSAIBOSSHQV-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- JLPJFSCQKHRSQR-UHFFFAOYSA-N oxolan-3-one Chemical compound O=C1CCOC1 JLPJFSCQKHRSQR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001696 purinergic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229950002821 resminostat Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
Definitions
- the invention relates to the field of medicinal chemistry, in particular to a compound and its preparation method and application
- the current methods of regulating the immune system to treat cancer mainly include tumor vaccines, recombinant cytokines, monoclonal antibodies, autologous T cell therapy, and small molecule immunomodulators. Because some tumor immune pathways and mechanisms can only be adjusted by small molecule drugs, small molecule drugs can regulate immune-related targets in the tumor microenvironment, which can expand the application range of tumor immunotherapy, and can also be tumor-targeted drugs and biological immunomodulators Combine therapies to find opportunities.
- Small molecule drugs can modulate immunosuppressive cells such as bone marrow-derived suppressor cells (MDSCs), dendritic cells (DCs), tumor-associated macrophages (TAMs), and these cells are usually not regulated by immune checkpoint inhibitors .
- MDSCs bone marrow-derived suppressor cells
- DCs dendritic cells
- TAMs tumor-associated macrophages
- the regulation of MDSCs, DCs and TAMs can be achieved through indoleamine 2,3-dioxygenase 1 (IDO1), arginase 1 (ARG1), inducible nitric oxide synthase (iNOS), and phosphodiesterase. -5 (PDE5) mediated, and the regulation of purinergic signal transduction can be mediated by ATP, CD39, CD73, adenosine, and elevated cAMP. Therefore, these targets may become the sites of action of small molecule drugs.
- IDO1 indoleamine 2,3-dioxygena
- the mechanism of action of arginase inhibitors is to further increase the proliferation of cytotoxic T cells and natural killer (NK) of the immune system by adjusting the tumor microenvironment, and exert its immunosuppressive effect to kill tumor cells.
- NO has a variety of positive cardiovascular physiological effects, such as relaxing blood vessels, regulating local blood flow, inhibiting the proliferation of vascular smooth muscle cells, inhibiting platelet adhesion and aggregation, and preventing thrombosis.
- Increasing the bioavailability of NO is expected to improve endothelial dysfunction, thereby delaying the occurrence and development of diabetic microvascular complications.
- NO is produced by NOS catalyzed by L-arginine, and arginase can compete with NOS for the common substrates ornithine and urea. Therefore, arginase inhibitors can reduce the competition between arginase and NOS, and promote the increase of NO production.
- arginase inhibitors can inhibit tumor growth in immune syngeneic mice. With the inhibition of tumor growth, the rapid increase in the local concentration of arginine leads to an increase in the number of CD3+ T cells in the tumor. Yudang indoleamine 2,3 dioxygenase (IDO) inhibitors block the degradation of tryptophan through IDO, which leads to the restoration of tumor and activated tryptophan levels in tumor-associated T cells.
- IDO Yudang indoleamine 2,3 dioxygenase
- arginase inhibitors can also be combined with other immuno-oncology therapeutic drugs that target T cell activation, such as CTLA-4 and PD-1 antibodies.
- CTLA-4 and PD-1 antibodies Such small molecule Arg inhibitors have broad application prospects in the treatment of renal cell carcinoma, breast cancer, non-small cell lung cancer, acute myeloid leukemia and Arg-mediated marrow-derived suppressor cell-related tumors. Its combination with biological monoclonal antibody will be the most feasible and effective plan.
- arginase inhibitors can effectively improve the endothelial function of T2DM microvascular complications.
- Arginase inhibitors can significantly improve the endothelial function of patients and promote Local microvascular blood flow increases, effectively delaying the occurrence and development of microvascular complications of T2DM.
- arginase inhibitors in diabetic nephropathy have also attracted attention.
- An animal study published in the American Journal of Physilogy in 2015 showed that arginase preparations can effectively delay the progression of diabetic nephropathy.
- Arginase inhibitors can increase renal medulla blood flow in diabetic mice and reduce urine protein.
- renal pathological biopsy showed that arginase inhibitors can significantly improve the progression of diabetic nephropathy. Investigating the reason, it was found that arginase inhibitors can significantly improve the activity of kidney NOS and increase the production of NO.
- arginase through MDSC/neutrophils. This enzyme can significantly reduce the level of arginine in the area surrounding the tumor. Once the body's immune cells are close to the tumor cells, energy deficiency will make them "weak” And inefficient. Therefore, inhibiting arginase can re-adjust the level of arginine around the tumor, charging the body's immune cells.
- Arginase inhibitors are known to enhance the effect of inhibiting tumor cell growth. At present, the research status of arginase preparations is as follows:
- the first batch of arginase inhibitors included boronic acid analogs (2) S-amino-6-boryl hexanoic acid and S-(2-boroethyl)-L-cysteine [S-(2- Both boronoethyl)-L-cysteine, BEC] inhibit the catalytic activity of arginase.
- the study found that the plane triangular borate (instead of the guanidine group) in arginine binds to the active site of arginase through metal bridging ions, causing the boron atom to have a nucleophilic attack, thereby forming a tetrahedral boric acid Salt ion.
- arginase inhibitor mainly represents N-hydroxy-L-arginine (NOHA) and N-hydroxy-n-L arginine (nor-NO-HA), which is characterized by N-hydroxy-guanidine X-ray diffraction analysis of the salt side chain shows that NOHA and nor-NO-HA inhibit arginase by replacing the metal bridge of arginase by N-hydroxyl group to bridge hydroxide ion. Based on this mechanism, nor-NO-HA is a more effective inhibitor.
- NOHA N-hydroxy-L-arginine
- nor-NO-HA N-hydroxy-n-L arginine
- paclitaxel-3'-O- ⁇ -D-glucopyranoside which is an important part of rhubarb extract, has anti-oxidation and inhibition of arginase.
- PG paclitaxel-3'-O- ⁇ -D-glucopyranoside
- arginine inhibitors are currently published, including INCB-001158 (incyte and Calithera) and resminostat (4SC) currently in clinical phase II, and CB-280 (Calithera) in clinical phase I, but it is still necessary Research more active arginine inhibitors.
- the technical problem to be solved by the present invention is to provide a compound and its preparation method and application.
- the compound provided by the present invention has high activity as an arginine inhibitor.
- the present invention provides a compound and a preparation method and application thereof.
- the compound with the structure of formula (I) provided by the present invention is obtained by selecting a specific main chain structure and its corresponding substituent
- the compound can be used as an arginase inhibitor with high activity and has potential therapeutic prospects in a variety of diseases.
- Figure 1 is a schematic diagram of pLVX plasmid map and arginase I insertion site
- Figure 2 is a detection diagram of arginase 1 content in a stable cell line
- Figure 3 shows the number of inoculated cells and the detection result of arginase activity
- FIG. 4 shows the results of the most suitable absorption wavelength
- Figure 5 shows the optimum concentration of enzyme, substrate and Mn 2+ .
- the present invention provides a compound having formula (I) or its tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , Or its pharmaceutically acceptable salt,
- the R 1 is selected from a hydroxyl group, a substituted or unsubstituted C1-C10 alkoxy group, or a substituted or unsubstituted C3-C30 acyloxyalkoxy group;
- the R 5 and R 6 are each independently selected from hydrogen atoms
- the R 2 is selected from substituted or unsubstituted C1-C15 alkoxy groups, substituted or unsubstituted C2-C8 acyl groups, substituted or unsubstituted C2-C15 unsaturated hydrocarbon groups, or substituted or unsubstituted C2-C15 unsaturated hydrocarbon groups
- the substituted C4-C10 heterocyclyloxy group wherein the substituents in the substituted alkoxy group, substituted acyl group, substituted unsaturated hydrocarbon group and substituted heterocyclyloxy group independently select deuterium, hydroxyl, Halogen, C3 ⁇ C10 cycloalkyl or 4-10 membered heterocyclic group;
- the R 3 is selected from hydrogen or formula (R 3 -1),
- the R 4 is selected from a substituted or unsubstituted C1-C15 alkoxy group, a substituted or unsubstituted C2-C8 acyl group, a substituted or unsubstituted C2-C15 unsaturated hydrocarbon group, or a substituted or unsubstituted C2-C15 unsaturated hydrocarbon group
- the substituted C4-C6 heterocyclyloxy group, wherein the substituents in the substituted alkoxy group, substituted acyl group, substituted unsaturated hydrocarbon group and substituted heterocyclyloxy group are independently selected from deuterium, hydroxyl , Halogen, C3 ⁇ C10 cycloalkyl or 4-10 membered heterocyclic group.
- the R 1 is preferably selected from hydroxyl, substituted or unsubstituted C2-C6 alkoxy or substituted or unsubstituted C6-C20 acyloxyalkoxy; wherein, the substituted
- the hydrogen in the alkoxy group and the substituted acyloxy alkoxy group may be substituted by one or more substituents, the substituents are preferably hydroxy or halogen;
- the R 1 is more preferably selected from hydroxy, methoxy, Ethoxy, propoxy, methyl acyloxy methoxy, ethyl acyloxy methoxy, n-propyl acyloxy methoxy, isopropyl acyloxy methoxy, n-butyl Acyloxy methoxy, isobutyl acyloxy methoxy, tert-butyl acyloxy methoxy, n-pentyl acyloxy methoxy, isopentyl acyloxy methoxy, ne
- the heterocyclic group is preferably an oxazolidinyl group;
- the R 2 is selected from substituted or unsubstituted C2-10 alkoxy, substituted or unsubstituted C3-C6 acyl, substituted or unsubstituted C3-C10 unsaturated hydrocarbon group or The substituted or unsubstituted C4-C8 heterocyclyloxy group, wherein any one or more hydrogens on the alkoxy group, acyl group, unsaturated hydrocarbon group and heterocyclyloxy group may be replaced by one or more Substituents are substituted, wherein the substituents are selected from deuterium, hydroxyl, halogen, C3-C10 cycloalkyl or 4-10 membered heterocyclic groups; wherein the unsaturated hydrocarbon group is preferably an alkynyl group; the R 2 More preferably, methoxy, ethoxy, propoxy, n-butoxy, isobutoxy, cyclopropylmethoxy, n-pentyloxy, n-he
- the R 4 is selected from substituted or unsubstituted C2-10 alkoxy, substituted or unsubstituted C3-C6 acyl, substituted or unsubstituted C3-C10 unsaturated hydrocarbon group or A substituted or unsubstituted C4-C8 heterocyclyloxy group, wherein any one or more of the substituted alkoxy group, substituted acyl group, substituted unsaturated hydrocarbon group or substituted heterocyclyloxy group Hydrogen may be substituted by one or more substituents, wherein the substituents are selected from deuterium, hydroxyl, halogen, C3-C10 cycloalkyl or 4-10 membered heterocyclic group; wherein, the unsaturated hydrocarbon group Preferably, it is an alkynyl group; the R 4 is more preferably methoxy, ethoxy, propoxy, n-butoxy, isobutoxy, cyclopropylmethoxy, n-penty
- the compound is selected from formula (I-A), formula (I-B), formula (I-C) or formula (I-D),
- the compound is selected from formula (I-E) and formula (I-F):
- R A is selected from C1-C15 alkyl or C3-C8 cycloalkyl
- Ring A is selected from C4-C10 heterocyclic groups, wherein the same carbon atom is connected to the oxygen atom and deuterium atom of ring A;
- the compound is selected from Formula (I-1), Formula (I-2), Formula (I-3), Formula (I-4), Formula (I-5), Formula (I-6) , Formula (I-7), Formula (I-8), Formula (I-9), Formula (I-10), Formula (I-11) or Formula (I-12),
- the present invention also provides a method for preparing a compound having a structure of (I-A), formula (I-B), (I-C) or (I-D), including:
- the R 1 is selected from a hydroxyl group, a substituted or unsubstituted C1-C10 alkoxy group, or a substituted or unsubstituted C3-C30 acyloxyalkoxy group;
- the R 5 and R 6 are each independently selected from hydrogen atoms
- the R 2 is selected from substituted or unsubstituted C1-C15 alkoxy groups, substituted or unsubstituted C2-C8 acyl groups, substituted or unsubstituted C2-C15 unsaturated hydrocarbon groups, or substituted or unsubstituted C2-C15 unsaturated hydrocarbon groups
- the substituted C4-C10 heterocyclyloxy group wherein the substituents in the substituted alkoxy group, substituted acyl group, substituted unsaturated hydrocarbon group and substituted heterocyclyloxy group independently select deuterium, hydroxyl, Halogen, C3 ⁇ C10 cycloalkyl or 4-10 membered heterocyclic group; said R 3 is selected from hydrogen or formula (R 3 -1),
- the R 4 is selected from a substituted or unsubstituted C1-C15 alkoxy group, a substituted or unsubstituted C2-C8 acyl group, a substituted or unsubstituted C2-C15 unsaturated hydrocarbon group, or a substituted or unsubstituted C2-C15 unsaturated hydrocarbon group
- the substituted C4-C6 heterocyclyloxy group, wherein the substituents in the substituted alkoxy group, substituted acyl group, substituted unsaturated hydrocarbon group and substituted heterocyclyloxy group are independently selected from deuterium, hydroxyl , Halogen, C3 ⁇ C10 cycloalkyl or 4-10 membered heterocyclic group.
- the present invention does not specifically limit the source of each raw material. Those skilled in the art can design a suitable route to synthesize each raw material according to actual needs. The present invention does not have special requirements on the reaction conditions. Those skilled in the art can follow the essence of the reaction Select appropriate reaction conditions. Specifically, the compound of the present invention is preferably prepared according to the following process:
- the present invention also provides an arginase inhibitor, including the compound of the formula (I) structure of the present invention or its tautomers, mesosomes, racemates, and enantiomers , Diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof; the compounds with the structure of formula (I) or tautomers, mesosomes, racemates, Enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof.
- the resulting compound can be used as an arginase inhibitor , And has high activity. Specifically, it increases the concentration of arginine in tumor tissues by inhibiting arginase activity, accelerates the proliferation of immune T cells and enhances their immune function, increases the response rate of tumor immune responses, and then enhances cells Inhibit the growth of tumor cells.
- the present invention also provides a tumor immunotherapy drug, including the compound of the formula (I) structure of the present invention or its tautomer, mesosome, racemate, enantiomer, non- Enantiomers, or mixtures thereof, or pharmaceutically acceptable salts thereof.
- the compounds of the present invention or their tautomers, mesosomes, racemates, enantiomers, diastereomers, or mixtures thereof, or their pharmaceutically acceptable salts are excluded from In addition to regulating the local concentration of arginine, as an arginase inhibitor, it can also be combined with other immuno-oncology therapeutic drugs that target T cell activation, such as CTLA-4 and PD-1 antibodies.
- arginase inhibitors have broad application prospects in the treatment of renal cell carcinoma, breast cancer, non-small cell lung cancer, acute myeloid leukemia, and arginine-mediated bone marrow-derived suppressor cell-related tumors. Its combination with biological monoclonal antibody will be the most feasible and effective plan.
- arginase inhibitors have potential therapeutic prospects for many diseases such as ischemia-regeneration perfusion injury (heart, lung, kidney), hypertension, atherosclerosis, diabetes, erectile dysfunction, pulmonary hypertension and so on.
- Substituted refers to one or more hydrogen atoms in the group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, independently of each other, substituted with a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without too much effort. For example, an amino group or a hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (eg, olefinic) bond.
- Cx ⁇ Cy heterocyclic group refers to the number of carbons in the heterocyclic group is x ⁇ y, x is the minimum value of carbon atoms and y is the maximum value of carbon atoms, and does not represent a heterocyclic group The size of the ring.
- x and y refer to the number of atoms forming the ring.
- substituted Cx ⁇ Cy groups refer to the number of carbons on the group and do not include substituents.
- substituted C1 ⁇ C15 alkoxy groups refer to alkoxy groups.
- the carbon number of is 1-15 and does not include the number of substituents.
- “Pharmaceutically acceptable salt” refers to certain salts of the above compounds that can maintain the original biological activity and are suitable for medical use.
- the pharmaceutically acceptable salt of the compound represented by formula (I) may be a metal salt or an amine salt formed with a suitable acid.
- “Pharmaceutical composition” means a mixture containing one or more compounds described herein or their physiologically pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically pharmaceutically acceptable carriers and excipients. Shape agent. The purpose of the pharmaceutical composition is to promote the administration of the biological body, and facilitate the absorption of the active ingredient to exert biological activity.
- Cis-3-(dibenzylamino)-N-methoxy-N-methylcyclobutanecarboxamide 8.12g (0.024mol) dissolved in 30ml tetrahydrofuran, cooled in an ice-salt bath, and added 0.5mol/L dropwise 3- 100ml (0.05mol) of butene magnesium bromide, control the temperature not higher than 5°C. After dripping, the reaction was allowed to warm up overnight. Adjust the pH to 5-6 with 1 mol/L hydrogen chloride solution, extract with ethyl acetate, wash and dry the organic phase with saturated brine, and flash column chromatography to obtain 5.4 g with a yield of 66%.
- Cis-2-Acetylamino-N-tert-butyl-2-(3-(dibenzylamino)cyclobutyl-6-(4,4,5,5-tetramethyl-1,3,2-di 1g (1.66mmol) of oxaborolan-2-yl)hexanamide was dissolved in 20ml of methanol, 0.1g of acetic acid, 0.3g of 5wt% palladium on carbon were added, and 3kg of pressure was hydrogenated for 16 hours. The palladium on carbon was removed by filtration and reduced in pressure. Concentrate to obtain 0.8 g of acetate.
- Cis-(S)-2-(3-((4'-(tetrahydrofuran-3-yloxy)-[1,1'-biphenyl]-4-yl)methylamino)cyclobutyl)-2 0.36 g (0.5 mmol, trifluoroacetate) of amino-6-boronic acid hexanoic acid was dissolved in 10 ml of DMF, 0.35 g (2.5 mmol) of potassium carbonate and 11 mg of bromoethane were added, and reacted at 5-10 degrees for 5 hours. Potassium carbonate was filtered out, DMF was concentrated to about 2ml, purified by pre-hplc, and lyophilized to obtain 182mg.
- Cis-2-Acetylamino-2-(3-aminocyclobutyl)-N-tert-butyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxolane Boran-2-yl)hexanamide acetate 1.68g (3.44mmol), (S)-4'-(tetrahydrofuran-3-yloxy)-4-formylbiphenyl 0.92g (3.44mmol) dissolved in Dichloromethane 30ml, 1.08g (5.28mmol) of sodium triacetoxyborohydride was added, and reacted overnight. Dilute with dichloromethane, stir with saturated sodium carbonate solution, separate the layers, wash the organic phase with saturated brine, and obtain 1.09gA by column chromatography.
- 0.56g (0.0023mol) of the intermediate was added to the reaction flask, and 0.34g (0.0023mol) of 4-formylphenylboronic acid, 0.22g (0.1mmol) of tetrakistriphenylphosphine oxide, 0.69g (0.0065mol) of sodium carbonate, and dioxygen were added.
- the hexacyclic ring was 10ml, water was 10ml, and the reaction system was replaced with argon three times, and reacted at 80°C for 4 hours.
- the reaction solution was poured into 20 ml of water, extracted with ethyl acetate, and the crude product was obtained by column chromatography to obtain 0.45 g, with a yield of 72.9%.
- Arginase can catalyze the conversion of L-arginine to L-ornithine and urea, so the level of arginase activity can be judged by detecting the content of urea in the solution at the end of the reaction. Based on the published methods, optimizations and improvements have been made. details as follows:
- Arginase I of human origin was dissolved in sterile deionized water containing 0.1% bovine serum albumin, and the stock solution concentration was 200 ⁇ g/mL.
- (S)-2-Amino-6-borocaproic acid and all candidate inhibitors are dissolved in dimethyl sulfoxide (DMSO), and the stock solution concentration is selected according to the weight of the compound provided (50mM/100mM). Both L-arginine (500mM) and magnesium sulfate (250mM) were prepared using sterile DMEM medium.
- each reaction concentration is set with 4-6 independent replicates, a total of 8 different concentration gradients.
- the inhibitor candidate dimethyl sulfoxide (DMSO) was dissolved and aliquoted, and the different concentration gradients shown in Table 4 were designed.
- DMSO dimethyl sulfoxide
- FIG. 1 is a schematic diagram of the pLVX plasmid map and the insertion site of arginase I;
- the inhibitor candidates for the preliminary screening are further screened at the cell level and tested for the cytological toxicity of the inhibitor, and finally an inhibitor compound with high efficiency and low toxicity is obtained.
- Figure 2 shows the detection diagram of Arginase 1 content in a stable cell line
- Day 1 Seed cells (96-well plate). Count and seed 0, 0.5, 1.0, 1.5, 2, 2.5, 3, 4 ( ⁇ 10 4 ) cells in sequence;
- Example 2 According to the screening method obtained in Example 2, the activity of the compound of the application as an arginine inhibitor was tested.
- the specific experimental method is as follows:
- L-arginine 500mM, DMEM
- anhydrous manganese sulfate 250mM, DMEM
- stop solution A ultrafiltered water
- stop solution B ultrafiltered water
- different concentrations of inhibitors 0.,0.001,0.01, 0.05, 0.1, 0.5, 1, 2, 5, 10, 50, 100 mM, DMSO).
- reaction system is:
- reaction is operated in a 96-well plate, 5 replicates/concentration/inhibitor.
- step 2 follows the system in step 2 to add each reaction component to the well plate, taking care not to generate bubbles.
- stop solution mixture a mixture of 75 ⁇ L of solution A and 75 ⁇ L of solution B
- Day 1 Inoculate the target cells. 2 ⁇ 10 4 pcs/well, 96-well plate, 3-5 wells repeated;
- the experimental group is the wells inoculated with cells, and the control group is the wells not inoculated with cells, both of which are 3-5 wells repeated.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组分名称 | 体积(μl) |
锰离子(250mM) | 1 |
L-精氨酸(500mM) | 1 |
精氨酸酶I(200μg/mL) | 0.25 |
抑制剂(不同浓度,使用浓度为0.1%) | 0.1 |
DMEM | 97.65 |
组分名称 | 体积(μl) |
试剂A | 75 |
试剂B | 75 |
抑制剂浓度(储存液,mM) | 体积(μl) | 终浓度(μM) |
0 | 0.1 | 0 |
0.01 | 0.1 | 0.01 |
0.05 | 0.1 | 0.05 |
0.1 | 0.1 | 0.1 |
0.5 | 0.1 | 0.5 |
1 | 0.1 | 1 |
2 | 0.1 | 2 |
5 | 0.1 | 5 |
组分 | 浓度 | 体积 |
L-精氨酸 | 500mM | 1μl |
抑制剂 | 相应不同浓度 | 0.1μl |
DMEM/F12空培 | 1× | 98.9μl |
Claims (14)
- 一种化合物,具有式(I)所示结构,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、溶剂化物、水合物、药学上可接受的盐或其混合物形式,其中:所述R 1选自羟基、取代的或未取代的C1~C10的烷氧基或取代的或未取代的C3~C30的酰氧基烷氧基;所述R 5和R 6各自独立地选自氢原子;或者,R 1与R 5和与它们相连接的氮和碳原子一起形成4~8元杂环基,优选为5~6元杂环基,其中,所述的杂环基内含有一个或多个N、O、S或SO 2,并且4~8元杂环上的氢任选进一步被一个或多个选自羟基、卤素、C1~C10烷基、C1~C10烷氧基或=O的取代基所取代;所述R 2选自取代的或未取代的C1~C15的烷氧基、取代的或未取代的C2~C8的酰基、取代的或未取代的C2~C15的不饱和烃基或取代的或未取代的C4~C10的杂环基氧基,其中,所述取代的烷氧基、取代的酰基、取代的不饱和烃基和取代的杂环基氧基中的取代基独立的选择氘、羟基、卤素、C3~C10环烷基或4~10元杂环基;所述R 3选自氢或式(R 3-1),所述R 4选自取代的或未取代的C1~C15的烷氧基、取代的或未取代的C2~C8的酰基、取代的或未取代的C2~C15的不饱和烃基或取代的或未取代的C4~C6的杂环基氧基,其中,所述取代的烷氧基、取代的酰基、取代的不饱和烃基和取代的杂环基氧基中的取代基独立的选自氘、羟基、卤素、C3~C10环烷基或4~10元杂环基。
- 根据权利要求1所述的化合物,其特征在于,所述化合物为式(I-A)、式(I-B)、(I-C)或(I-D):其中,所述R 1选自羟基、取代的或未取代的C1~C10的烷氧基或取代的或未取代的C3~C30的酰氧基烷氧基;所述R 2选自取代的或未取代的C1~C15的烷氧基、取代的或未取代的C2~C8的酰基、取代的或未取代的C2~C15的不饱和烃基或取代的或未取代的C4~C10的杂环基氧基,其中,所述取代的烷氧基、取代的酰基、取代的不饱和烃基和取代的杂环基氧基中的取代基独立的选择氘、羟基、卤素、C3~C10环烷基或4~10元杂环基;所述R 4选自取代的或未取代的C1~C15的烷氧基、取代的或未取代的C2~C8的酰基、取代的和未取代的C2~C15的不饱和烃基或取代的或未取代的C4~C6的杂环基氧基,其中,所述取代的烷氧基、取代的酰基、取代的不饱和烃基或取代的杂环基氧基中的取代基独立的选自氘、羟基、卤素、C3~C10环烷基或4~10元杂环基。
- 根据权利要求1~3任一项所述的化合物,其特征在于,所述R 1选自羟基、C2~C6的烷氧基或C6~C20的酰氧基烷氧基;或者,R 1与R 5和与它们相连接的氮和碳原子一起形成氧代恶唑烷基。
- 根据权利要求1~3任一项所述的化合物,其特征在于,所述R 1选自羟基、甲氧基、乙氧基、丙氧基、甲基酰氧基甲氧基、乙基基酰氧基甲氧基、正丙基酰氧基甲氧基、异丙基酰氧基甲氧基、正丁基酰氧基甲氧基、异丁基酰氧基甲氧基、叔丁基酰氧基甲氧基、正戊基酰氧基甲氧基、异戊基基酰氧基甲氧基、新戊基酰氧基甲氧基、甲基酰氧基乙氧基、乙基基酰氧基乙氧基、正丙基酰氧基乙氧基、异丙基酰氧基乙 氧基、正丁基酰氧基乙氧基、异丁基酰氧基乙氧基、叔丁基酰氧基乙氧基、正戊基酰氧基乙氧基、异戊基基酰氧基乙氧基、新戊基酰氧基乙氧基;或者,R 1与R 5和与它们相连接的氮和碳原子一起形成氧代恶唑烷基。
- 根据权利要求1或2所述的化合物,其特征在于,所述R 2选自C2~10的烷氧基、C3~C6的酰基、C3~C10的不饱和烃基或C4~C8的杂环基氧基,其中,所述的烷氧基任选进一步被C3~C10环烷基取代;所述不饱和烃基优选为炔基。
- 根据权利要求1~3任意一项所述的化合物,其特征在于,所述R 2选自甲氧基、乙氧基、丙氧基、正丁氧基、异丁氧基、环丙甲氧基、正戊基氧基、正己基氧基、乙酰基、正丙基酰基、异丙基酰基、丁基酰基、戊基酰基、乙烯基、乙炔基、丙烯基、丙炔基、四氢呋喃-3-基氧基、四氢呋喃-2-基氧基、四氢吡喃-3-基氧基或四氢吡喃-2-基氧基。
- 根据权利要求1~3任意一项所述的化合物,其特征在于,所述R 4选自C2~10的烷氧基、C3~C6的酰基、C3~C10的不饱和烃基或C4~C8的杂环基氧基,其中,所述不饱和烃基优选为炔基。
- 一种具有式(I)结构的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其可药用盐的制备方法,包括:1)将式(II)结构的化合物和式(III)结构的化合物反应,得到式(IV)结构的化合物;2-A)将得到的式(IV)结构的化合物转化为式(I-A)的化合物;2-B)将得到的式(IV)结构的化合物与式(V)反应得到式(VI)结构的化合物,再将式(VI)结构的化合物转化为式(I-B),2-C)将得到的(I-A)化合物在酸性条件下与多聚甲醛反应,转化为式(I-C),2-D)将得到的(I-B)化合物酸性条件下与多聚甲醛反应,转化为式(I-D),其中:所述R 1选自羟基、取代的或未取代的C1~C10的烷氧基或取代的或未取代的C3~C30的酰氧基烷氧基;所述R 5和R 6各自独立地选自氢原子;或者,R 1与R 5和与它们相连接的氮和碳原子一起形成4~8元杂环基,优选为5~6元杂环基,其中,所述的杂环基内含有一个或多个N、O、S或SO 2,并且4~8元杂环上的氢任选进一步被一个或多个选自羟基、卤素、C1~C10烷基、C1~C10烷氧基或=O的取代基所取代;所述R 2选自取代的或未取代的C1~C15的烷氧基、取代的或未取代的C2~C8的酰基、取代的或未取代的C2~C15的不饱和烃基或取代的或未取代的C4~C10的杂环基氧基,其中,所述取代的烷氧基、取代的酰基、取代的不饱和烃基和取代的杂环基氧基中的取代基独立的选择氘、羟基、卤素、C3~C10环烷基或4~10元杂环基;所述R 3选自氢或式(R 3-1),所述R 4选自取代的或未取代的C1~C15的烷氧基、取代的或未取代的C2~C8的酰基、取代的或未取代的C2~C15的不饱和烃基或取代的或未取代的C4~C6的杂环基氧基,其中,所述取代的烷氧基、取代的酰基、取代的不饱和烃基和取代的杂环基氧基中的取代基独立的选自氘、羟基、卤素、C3~C10环烷基或4~10元杂环基。
- 一种药物组合物,所述的药物组合物包括有效剂量的权利要求1~9中任何一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、溶剂化物、水合物、药学上可接受的盐或其混合物形式。
- 一种精氨酸酶抑制剂,包括权利要求1~9任意一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其可药用盐或权利要求11所述的药物组合物。
- 一种肿瘤免疫治疗药物,包括权利要求1~9任意一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其可药用盐或权利要求11所述的药物组合物。
- 一种缺血再生灌注损伤、高血压、动脉粥样硬化、糖尿病、勃起功能障碍或肺动脉高压的治疗药物,包括权利要求1~9任意一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其可药用盐或权利要求11所述的药物组合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910547881.1A CN112110944B (zh) | 2019-06-21 | 2019-06-21 | 一种化合物及其制备方法和应用 |
CN201910547881.1 | 2019-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020253352A1 true WO2020253352A1 (zh) | 2020-12-24 |
Family
ID=73795414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/085842 WO2020253352A1 (zh) | 2019-06-21 | 2020-04-21 | 一种化合物及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112110944B (zh) |
WO (1) | WO2020253352A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103068830A (zh) * | 2010-04-22 | 2013-04-24 | 马尔斯公司 | 精氨酸酶抑制剂及其治疗应用 |
CN104244932A (zh) * | 2011-10-19 | 2014-12-24 | 马尔斯公司 | 精氨酸酶抑制剂和其治疗应用 |
CN104540836A (zh) * | 2012-04-18 | 2015-04-22 | 马尔斯公司 | 作为精氨酸酶抑制剂的环约束类似物 |
CN108794517A (zh) * | 2017-04-27 | 2018-11-13 | 南京谷睿生物科技有限公司 | 一种精氨酸酶抑制剂及其制备方法与用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10143699B2 (en) * | 2015-06-23 | 2018-12-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
-
2019
- 2019-06-21 CN CN201910547881.1A patent/CN112110944B/zh active Active
-
2020
- 2020-04-21 WO PCT/CN2020/085842 patent/WO2020253352A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103068830A (zh) * | 2010-04-22 | 2013-04-24 | 马尔斯公司 | 精氨酸酶抑制剂及其治疗应用 |
CN104244932A (zh) * | 2011-10-19 | 2014-12-24 | 马尔斯公司 | 精氨酸酶抑制剂和其治疗应用 |
CN104540836A (zh) * | 2012-04-18 | 2015-04-22 | 马尔斯公司 | 作为精氨酸酶抑制剂的环约束类似物 |
CN108794517A (zh) * | 2017-04-27 | 2018-11-13 | 南京谷睿生物科技有限公司 | 一种精氨酸酶抑制剂及其制备方法与用途 |
Also Published As
Publication number | Publication date |
---|---|
CN112110944A (zh) | 2020-12-22 |
CN112110944B (zh) | 2022-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7097880B2 (ja) | Malt1分解のための化合物 | |
KR102485620B1 (ko) | Acc 억제제 및 그의 고체 형태를 제조하는 방법 | |
JP6644792B2 (ja) | ベンザゼピンスルホンアミド化合物 | |
CN111868026B (zh) | 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途 | |
JP5583592B2 (ja) | Ido阻害剤 | |
JP2017538678A (ja) | 免疫調節剤 | |
CA2981657A1 (en) | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer | |
CN111410661B (zh) | 帽依赖性内切核酸酶抑制剂及其用途 | |
JP2020512399A (ja) | Idoを抑制する化合物、その調製方法及びその使用 | |
WO2015010297A1 (en) | Therapeutically active compounds and their methods of use | |
CN113387840B (zh) | PD-1/PD-L1和HDACs双靶点抑制剂、制备方法和用途 | |
JP2020527166A (ja) | Bcl−2タンパク質を阻害するためのN−ベンゼンスルホニルベンズアミド系化合物、その組成物および使用 | |
CN104010501A (zh) | 含src同源区2蛋白酪胺酸磷酸酶-1增效剂及其治疗方法 | |
CA2946609A1 (en) | Naphthaquinone methyltransferase inhibitors and uses thereof | |
EP2350039A1 (en) | Viral polymerase inhibitors | |
RU2704251C2 (ru) | П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения | |
JP2006527206A (ja) | パピローマウイルスのインヒビター | |
WO2020253352A1 (zh) | 一种化合物及其制备方法和应用 | |
WO2020187292A1 (zh) | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 | |
CN112876411A (zh) | 化合物及其在合成pdl1拮抗剂类药物分子中的应用 | |
CN108794517B (zh) | 一种精氨酸酶抑制剂及其制备方法与用途 | |
TW201934547A (zh) | 一種嘧啶類化合物、其製備方法及其醫藥用途 | |
CA3030697C (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
TW201922690A (zh) | 環-amp反應元素結合蛋白的抑制劑 | |
JP2024516194A (ja) | Pd1/pd-l1阻害剤としての化合物及びその方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20825614 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20825614 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20825614 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 30/06/2022) |